Mirati Therapeutics Inc., a company developing medicines for targeted oncology, announced the pricing of an underwritten public offering at $45 million.
The San Diego-based company is offering 2,250,000 shares of its common stock to the public for $20 per share, according to a recent press release.
Mirati officials said the company will use the net proceeds for general corporate purposes, which may include clinical trials and other research and development expenses for its ongoing oncology clinical development programs.
Citigroup, Jefferies and Leerink Partners are acting as joint book-running managers in the offering.